dc.contributor.author | Aktas, Burak Y. | |
dc.contributor.author | Aktas, Ozge Ozturk | |
dc.date.accessioned | 2021-06-03T05:20:01Z | |
dc.date.available | 2021-06-03T05:20:01Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 0028-4793 | |
dc.identifier.uri | http://dx.doi.org/10.1056/NEJMc1912185 | |
dc.identifier.uri | http://hdl.handle.net/11655/23963 | |
dc.description.abstract | To the Editor: In the randomized, placebo-controlled Vitamin D and Type 2 Diabetes (D2d) trial involving persons at risk for type 2 diabetes, Pittas et al. (Aug. 8 issue)(1) found that vitamin D-3 supplementation at a dose of 4000 IU per day did not result in a significantly lower risk of diabetes than placebo. Investigators emphasized that the trial was planned not only for participants with vitamin D insufficiency, given ethical considerations. Although the mean baseline vitamin D levels are well balanced between the trial groups and above insufficiency limits, more than 20% of the participants in the placebo group . . . | |
dc.language.iso | en | |
dc.relation.isversionof | 10.1056/NEJMc1912185 | |
dc.rights | Attribution 4.0 United States | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Vitamin D Supplementation And Prevention Of Type 2 Diabetes | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | New England Journal Of Medicine | |
dc.contributor.department | İç Hastalıkları | |
dc.identifier.volume | 381 | |
dc.identifier.issue | 18 | |
dc.description.index | WoS | |